Comparison of patient-reported outcomes with quetiapine extended release and quetiapine immediate release in patients with stable schizophrenia - the eXtRa Study

被引：0
|
作者：
Riedel, M. [1 ]
Schmitz, M. [2 ]
Ostergaard, P. Kare
Ferrannini, L. [3 ]
Franco, M. A. [4 ]
Alfano, V. [5 ]
Vansvik, E. Dencker [6 ]
机构：
[1] Vinzenz von Paul Hosp, Rottweil, Germany
[2] Inst Psychosomat Med, Psychiatrist Off, Vienna, Austria
[3] ASL3, Dept Mental Hlth & Addict, Genoa, Italy
[4] Zamora Hosp, Dept Psychiat, Zamora, Spain
[5] Parthenope Univ, Dept Studies Inst & Territorial Syst, Naples, Italy
[6] AstraZeneca, Sodertalje, Sweden
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2012年 / 22卷
关键词：
D O I：
10.1016/S0924-977X(12)70523-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S339 / S339
页数：1
相关论文
共 50 条
  • [21] Once-daily quetiapine sustained release (SR) is effective and well tolerated in patients with schizophrenia switched from the same total daily dose of quetiapine immediate release (IR)
    Naber, D.
    Schimmelmann, B. G.
    Huber, C. G.
    Hundemer, H. P.
    Schacht, A.
    Wagner, T. T.
    Lambert, M.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 449 - 449
  • [22] Extended release Quetiapine Fumarate (Quetiapine XR) monotherapy in the treatment of patients with major depressive disorder (MDD)
    Montgomery, S.
    Cutler, A.
    Lazarus, A.
    Schollin, M.
    Brecher, M.
    EUROPEAN PSYCHIATRY, 2008, 23 : S259 - S260
  • [23] Efficacy of extended release Quetiapine Fumarate (Quetiapine XR) in patients with severe Major Depressive Disorder (MDD)
    Svedater, H.
    Thase, M.
    Locklear, J.
    Datto, C.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2009, 13 : 43 - 44
  • [24] Pharmacobezoar Associated Prolonged Clinical Course in a Patient with Immediate Release Quetiapine Overdose
    Inoue, Fumiya
    Okazaki, Yuji
    Huh, Kyungko
    Ichiba, Toshihisa
    Chiba, Takuyo
    Namera, Akira
    JOURNAL OF MEDICAL TOXICOLOGY, 2024, 20 (04) : 430 - 433
  • [25] Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes
    Compton, Wilson M.
    Volkow, Nora D.
    JAMA NETWORK OPEN, 2021, 4 (05)
  • [26] THE IMPACT OF ONCE-DAILY EXTENDED-RELEASE QUETIAPINE FUMARATE (QUETIAPINE XR) ON LENGTH AND COSTS OF HOSPITALISATION OF PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
    Locklear, J. C.
    Wahlqvist, P.
    Gustafsson, U.
    Udd, M.
    Fajutrao, L.
    Eriksson, H.
    VALUE IN HEALTH, 2011, 14 (07) : A299 - A299
  • [27] Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia
    Ganesan, S.
    Agarnbaram, V.
    Randeree, F.
    Eggens, I.
    Huizar, K.
    Meulien, D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 21 - 32
  • [28] Self-Reported Sedation Profile of Immediate-Release Quetiapine Fumarate Compared With Extended-Release Quetiapine Fumarate During Dose Initiation: A Randomized, Double-Blind, Crossover Study in Healthy Adult Subjects
    Datto, Catherine
    Berggren, Lovisa
    Patel, Jitendra B.
    Eriksson, Hans
    CLINICAL THERAPEUTICS, 2009, 31 (03) : 492 - 502
  • [29] Efficacy of extended release quetiapine fumarate (quetiapine XR) monotherapy on sleep disturbance in patients with major depressive disorder
    Papakostas, G.
    Bandelow, B.
    Demyttenaere, K.
    Trivedi, M.
    Earley, W.
    Szamosi, J.
    Eriksson, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 159 - 159
  • [30] Efficacy of extended release quetiapine fumarate (quetiapine XR) monotherapy and adjunct therapy in patients with major depressive disorder
    Kalali, A.
    Montgomery, S.
    Earley, W.
    Szamosi, J.
    Eriksson, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 151 - 151
12345